Clinical Trials on Hyperparathyroidism, Secondary in United Kingdom

Total 753 results

Amgen

Completed

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

Belgium, United States, Germany, Poland, United Kingdom, Lithuania
Deltanoid Pharmaceuticals

Completed

A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

United States
KAI Pharmaceuticals

Completed

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

United States
Amgen

Recruiting

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism

Spain, Belgium, Germany, Czechia, Poland, France, Greece, Hungary, Italy, United Kingdom, Lithuania, Portugal
OPKO Health, Inc.

Completed

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

Secondary Hyperparathyroidism | Vitamin D Insufficiency

United States
National Center for Research Resources (NCRR)

Completed

Acute Regulation of Parathyroid Hormone by Dietary Phosphate

Secondary Hyperparathyroidism

United States
Genzyme, a Sanofi Company

Completed

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

Secondary Hyperparathyroidism

United States
Kerstyn C. Zalesin, M.D.
Abbott

Completed

Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery (ExtenD)

Gastric Bypass | Parathyroid Hormone

United States
University of Maryland, Baltimore

Completed

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism (1hydroxylase)

Secondary Hyperparathyroidism

United States
Amgen

Completed

Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease

Chronic Kidney Disease | Secondary Hyperparathyroidism | Hyperparathyroidism, Secondary

United States, Germany, United Kingdom
Genzyme, a Sanofi Company

Completed

A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis

Secondary Hyperparathyroidism

United States
Genzyme, a Sanofi Company

Completed

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

Secondary Hyperparathyroidism

United States
Montefiore Medical Center

Terminated

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

Secondary Hyperparathyroidism | Hypercalcemia

United States
Amgen

Completed

Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis

Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis

United States
Roxane Laboratories

Completed

Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions

Hypocalcemia | Secondary Hyperparathyroidism

United States
Amgen

Completed

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

Secondary Hyperparathyroidism, Chronic Kidney Disease

United States, Czechia, Germany, France, Hungary, Greece, Belgium, Italy, Poland, Russian Federation, Ukraine
Sanofi

Active, not recruiting

Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis

Secondary Hyperparathyroidism-Chronic Kidney Disease

United States, Chile
Amgen

Terminated

Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

United States, Belgium, Italy, Hungary, Czechia, France, Germany, Greece, Spain, Poland, Russian Federation, Ukraine, New Zealand, Slovakia, Lithuania, Portugal
OPKO Health, Inc.

Completed

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

Vitamin D Insufficiency | CKD Stage 4 | CKD Stage 3 | Secondary Hyperparathyroidism Due to Renal Causes

United States
KAI Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Hyperparathyroidism, Secondary

United States, Australia
Weill Medical College of Cornell University

Completed

Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity

Obesity | Vitamin D Deficiency | Secondary Hyperparathyroidism

United States
Emory University

Terminated

Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Transplant Patients (PAD)

Hyperparathyroidism, Secondary

United States
Amgen

Completed

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease (BONAFIDE)

Secondary Hyperparathyroidism

United States, Italy, Belgium, Switzerland, Hungary, Spain, Turkey, Poland, Portugal, United Kingdom, Czech Republic, Macedonia, The Former Yugoslav Republic of
Abbott

Completed

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D (IMPACT SHPT)

Hemodialysis | Chronic Kidney Disease | Secondary Hyperparathyroidism

United States, Czech Republic, Denmark, Germany, Greece, Italy, Netherlands, Portugal, Russian Federation, Spain, Sweden, United Kingdom
Atlanta VA Medical Center
Emory University

Completed

Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease (POSH-D)

Kidney Disease

United States
Abbott

Completed

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States
University of Colorado, Denver

Completed

Trial to Optimize Mineral Outcomes in Dialysis Patients

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States
OPKO Health, Inc.

Completed

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism | Vitamin D Insufficiency

United States
Kenneth R. Phelps, M.D.
Genzyme, a Sanofi Company

Completed

Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

Hyperparathyroidism | Chronic Kidney Disease

United States
Washington University School of Medicine
Abbott; NorthShore University HealthSystem; Northwestern University Feinberg... and other collaborators

Completed

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) (PACE)

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States
OPKO Health, Inc.

Active, not recruiting

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

Chronic Kidney Diseases | Vitamin D Deficiency | Stage 5 Chronic Kidney Disease | Secondary Hyperparathyroidism Due to Renal Causes

United States
Genzyme, a Sanofi Company

Completed

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Renal Failure | Secondary Hyperparathyroidism | Chronic Renal Insufficiency

United States, Puerto Rico
Abbott

Completed

A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Disease

Secondary Hyperparathyroidism | Chronic Kidney Disease, Stage 5

United States
Abbott

Completed

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

End Stage Renal Disease | Secondary Hyperparathyroidism

United States
Amgen

Terminated

Pediatric Chronic Kidney Disease Safety and Efficacy

Hyperparathyroidism | Chronic Kidney Disease | Secondary Hyperparathyroidism | Hyperparathyroidism, Secondary | Kidney Disease

United States, Belgium, Hungary, Spain, Australia, Germany, Poland, Mexico, Russian Federation, Slovakia
AbbVie

Recruiting

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD) | Secondary Hyperparathyroidism (SHPT)

United States, Puerto Rico
Amgen

Completed

Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States, Italy, Belgium, Denmark, Switzerland, Canada, Turkey, Spain, Austria, Germany, Hungary, Greece, France, Poland, Russian Federation, Czechia, Latvia, Lithuania, New Zealand, Portugal, Sweden, Estonia
University of Virginia

Withdrawn

Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States
OPKO IP Holdings II, Inc.

Completed

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism | Chronic Renal Failure | Chronic Renal Insufficiency

United States
Salem Veterans Affairs Medical Center
Abbott

Completed

Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease | Secondary Hyperparathyroidism

United States
OPKO IP Holdings II, Inc.

Completed

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

Chronic Kidney Disease | Secondary Hyperparathyroidism | Chronic Renal Failure | Chronic Renal Insufficiency

Canada, United States
Sheffield Teaching Hospitals NHS Foundation Trust

Completed

Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery

Total Thyroidectomy | Bilateral Neck Exploration for Primary Hyperparathyroidism

United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Fluoptics Ltd, Grenoble, France

Completed

Near Infrared Fluorescent Imaging in Thyroid and Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics

Primary Hyperparathyroidism

United Kingdom
OPKO IP Holdings II, Inc.

Completed

Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

Chronic Kidney Disease | Secondary Hyperparathyroidism | Chronic Renal Failure | Chronic Renal Insufficiency

United States
Amgen

Completed

Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide

Hyperparathyroidism, Secondary

United States
University of California, Los Angeles
Loma Linda University

Completed

FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease

Secondary Hyperparathyroidism

United States
Amgen

Recruiting

A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, United States, Turkey, India, Singapore, Taiwan, Argentina, Malaysia, Russian Federation, Ukraine
AbbVie (prior sponsor, Abbott)
North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)

Terminated

Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

End-Stage Renal Disease | Secondary Hyperparathyroidism

United States
Indiana University School of Medicine

Completed

Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease

Renal Osteodystrophy

United States
Pathalys Pharma
Launch Therapeutics

Recruiting

Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 (PATH-2)

Secondary Hyperparathyroidism | End Stage Kidney Disease

United States, Bulgaria, Portugal, Spain, Poland, Serbia

Clinical Trials on Hyperparathyroidism, Secondary in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations